BioArctic: Interim Report for the period April - June 2026

EarningsLeqembiPositive

AI Analysis

Summary

BioArctic reported interim results for Q2 2026 with new approvals for Leqembi and additional strategic partnerships. Eisai provided a sales forecast of JPY 143.5 billion for Leqembi in fiscal year 2026.

Financial Highlights

Guidance

Eisai provided sales forecast for Leqembi of JPY 143.5 billion for fiscal year 2026 (April 2026 to March 2027)

Importance:5/10

Sentiment:

0.50

interim reportearningsLeqembisales forecaststrategic partnerships

Related Companies

$BIOA-B.ST $ESALY

Read the original article

Published by PR Newswire Biotech on August 26, 2026 6:43 AM

Read Original